Solasia Pharma K.K.

Company Profile

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

22

Website

www.solasia.co.jp

Country

Japan

Exchange

Tokyo

Founded 2006Minato, Japan

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices globally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis.

Its portfolio also includes DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma, and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy

SP-05, which is in a preclinical trial for colorectal cancer. in September 2008. Solasia Pharma K.K. The company was formerly known as JapanBridge, Inc. and changed its name to Solasia Pharma K.K. was founded in 2006 and is headquartered in Minato, Japan.

Key Stats

52-Week Range

¥21.00¥47.00

Beta1.20

Trailing P/EN/A

Forward P/E-13.33

Trailing EPS-3.33

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.